Open Orphan #ORPH – Court Approval to facilitate Distribution in Specie

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that, following its announcement on 13 April 2021, it has received Court approval for the reduction in capital. The reduction of capital will become effective on […]

Open Orphan #ORPH – Potential demerger of certain non-core assets

Open Orphan plc ((AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials,announces that it is at an advanced stage in planning for a possible spin-out of certain non-core Development IP Assets. These Development IP Assets are a portfoilio […]